The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Antithrombotic Therapy in Patients With Chronic Kidney Disease
Open accessAbstract
C hronic kidney disease (CKD) is a pandemic public health problem, with Ͼ500 million people worldwide estimated to have some form of kidney injury. 1 Survey data suggest that the prevalence of CKD in the United States has increased between 1988 to 1994 and 1999 to 2004 from 10% to 13%, reaching a rate of 14% in 2010.2,3 Overlapping conditions such as acute kidney injury play an important role in the growing epidemiology of CKD, and underlying CKD is in turn an important risk factor for acute kidney injury and end-stage renal disease.Key factors contributing to the increased prevalence of CKD include the aging population and the growing burden of diabetes mellitus.4 The prevalence of stage 3 or 4 CKD has been reported to be Ϸ38% for adults Ն70 years old versus Ϸ1% in adults 20 to 39 years of age.2,5 Patients with diabetes mellitus are found to present with CKD in about one third of cases, with diabetic nephropathy as the most common cause of renal impairment.6 Notably, numerous epidemiological studies have shown that patients with all stages of CKD experience higher rates of atherothrombotic disease manifestations and processes with thromboembolic potential such as atrial fibrillation than the general population.[7][8][9][10] This underscores the importance of antithrombotic treatment strategies in these patients.However, the risk-tobenefit ratio with antithrombotic therapies may be altered in CKD.In fact, patients with CKD also have an increased risk of bleeding complications.[11][12][13] Importantly, bleeding has emerged as an independent predictor of adverse outcomes, including mortality.14 -17 Moreover, patients with severe CKD are less likely to receive medications of proven benefit.18,19 Overall, these findings contribute to explain why patients with reduced renal function have poorer prognosis compared with patients with preserved renal function.Defining the fine balance between safety and efficacy remains a challenge in patients with CKD treated with antithrombotic therapy.Unfortunately, dosing errors, which commonly occur in patients with CKD, accounts for almost one third of adverse drug events, and more than half of these errors occur at the prescription stage.20 Therefore, understanding whether a drug should or should not be prescribed and individualizing dosage regimens are key to balancing the safety and efficacy profiles of antithrombotic medications in CKD patients.This article provides an overview of the currently available evidence on the use of antithrombotic therapy in patients with CKD.In particular, a description of thrombosis and hemostatic profiles that characterize CKD patients, considerations for use of antithrombotic agents, including antiplatelet and anticoagulant therapies, and a review of the safety and efficacy data in CKD patients in the settings of coronary artery disease manifestations and atrial fibrillation are provided.A discussion of antithrombotic therapy in patients with acute kidney injury and end-stage renal disease is beyond the scope of this article. CKD: DefinitionsThe Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation defines CKD as either kidney damage or a decreased kidney glomerular filtration rate (GFR) of Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 for Ն3 months.21 The different stages of CKD are listed in Table 1.While stages 3 through 5 are characterized by a gradient of GFR ranges, markers of structural or functional kidney damage other than GFR, including blood, urine, or imaging tests abnormalities, need to be present to establish a diagnosis of stage 1 and stage 2 CKD.Kidney failure is defined as either a GFR of Ͻ15 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 or a need for initiation of kidney replacement therapy (dialysis or transplantation).End-stage renal disease is a US administrative definition that includes patients treated by dialysis or transplantation regardless of the GFR level.Many calculators are available to estimate the GFR.The National Kidney Foundation recommends using the Modification of Diet in Renal Disease equation.22 Thrombosis and Hemostasis: Biological Considerations in Patients With CKDPatients with CKD may present with platelet dysfunction and abnormalities in the enzymatic coagulation cascade.This may explain why patients with CKD may experience 2 opposite hemostatic complications: bleeding diathesis and thrombotic tendencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention
Bates, D. W. (1995) · JAMA · doi:10.1001/jama.1995.03530010043033 · Cited by 2,127
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa055443 · Cited by 1,228
Pharmacokinetics and drug metabolism in the elderly
Klotz, U. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902722679 · Cited by 826
Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr342 · Cited by 608
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Mahaffey, K. W., Wojdyla, D. M., Carroll, K., Becker, R. C., Storey, R. F., Angiolillo, D. J., Held, C., Cannon, C. P., James, S., Pieper, K. S., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.047498 · Cited by 434
Self-citation
Cited by
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0243 · Cited by 458
Metadata
- Authors
- Capodanno, D., & Angiolillo, D. J.
- Venue
- Circulation
- Published
- 2012-05-29
- Volume
- 125
- Issue
- 21
- Pages
- 2649-2661
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2061089824
- Cited by
- 165
- References
- 12
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.